Assenagon Asset Management S.A. lowered its position in shares of STERIS plc (NYSE:STE - Free Report) by 96.0% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 6,030 shares of the medical equipment provider's stock after selling 145,933 shares during the quarter. Assenagon Asset Management S.A.'s holdings in STERIS were worth $1,367,000 at the end of the most recent reporting period.
Other hedge funds also recently made changes to their positions in the company. Avalon Trust Co bought a new stake in STERIS in the 4th quarter valued at $30,000. Human Investing LLC bought a new position in shares of STERIS in the fourth quarter valued at about $31,000. Anfield Capital Management LLC lifted its stake in shares of STERIS by 100.0% during the 4th quarter. Anfield Capital Management LLC now owns 182 shares of the medical equipment provider's stock worth $37,000 after buying an additional 91 shares during the last quarter. Brown Brothers Harriman & Co. lifted its stake in shares of STERIS by 66.7% during the 4th quarter. Brown Brothers Harriman & Co. now owns 220 shares of the medical equipment provider's stock worth $45,000 after buying an additional 88 shares during the last quarter. Finally, Versant Capital Management Inc grew its stake in STERIS by 70.1% in the 1st quarter. Versant Capital Management Inc now owns 262 shares of the medical equipment provider's stock valued at $59,000 after buying an additional 108 shares during the last quarter. 94.69% of the stock is owned by institutional investors.
Insider Activity at STERIS
In other news, CEO Daniel A. Carestio sold 17,626 shares of STERIS stock in a transaction on Thursday, June 5th. The stock was sold at an average price of $242.56, for a total value of $4,275,362.56. Following the completion of the transaction, the chief executive officer now directly owns 51,385 shares in the company, valued at approximately $12,463,945.60. The trade was a 25.54% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Cary L. Majors sold 12,828 shares of the business's stock in a transaction that occurred on Tuesday, May 20th. The shares were sold at an average price of $250.08, for a total transaction of $3,208,026.24. Following the transaction, the senior vice president now directly owns 11,372 shares of the company's stock, valued at approximately $2,843,909.76. This represents a 53.01% decrease in their position. The disclosure for this sale can be found here. 1.07% of the stock is owned by company insiders.
STERIS Price Performance
Shares of NYSE STE traded down $0.93 during trading hours on Wednesday, hitting $236.15. 540,879 shares of the stock were exchanged, compared to its average volume of 548,012. STERIS plc has a 1-year low of $200.98 and a 1-year high of $252.79. The company has a market cap of $23.23 billion, a PE ratio of 38.09 and a beta of 0.94. The company has a debt-to-equity ratio of 0.29, a quick ratio of 1.39 and a current ratio of 1.96. The company's fifty day simple moving average is $233.70 and its two-hundred day simple moving average is $223.01.
STERIS (NYSE:STE - Get Free Report) last posted its quarterly earnings data on Wednesday, May 14th. The medical equipment provider reported $2.74 earnings per share for the quarter, topping the consensus estimate of $2.59 by $0.15. The company had revenue of $1.48 billion during the quarter, compared to analysts' expectations of $1.47 billion. STERIS had a net margin of 11.26% and a return on equity of 14.21%. STERIS's revenue for the quarter was up 5.7% compared to the same quarter last year. During the same period in the prior year, the company posted $2.58 earnings per share. On average, sell-side analysts predict that STERIS plc will post 9.08 EPS for the current year.
STERIS Dividend Announcement
The business also recently declared a quarterly dividend, which will be paid on Thursday, June 26th. Investors of record on Tuesday, June 10th will be issued a $0.57 dividend. This represents a $2.28 dividend on an annualized basis and a dividend yield of 0.97%. The ex-dividend date is Tuesday, June 10th. STERIS's dividend payout ratio (DPR) is currently 36.77%.
Analyst Upgrades and Downgrades
Several equities analysts have recently commented on the company. Stephens reaffirmed an "overweight" rating and issued a $250.00 target price on shares of STERIS in a research report on Thursday, May 15th. JMP Securities increased their price objective on STERIS from $265.00 to $280.00 and gave the stock a "market outperform" rating in a research report on Friday, May 16th. Morgan Stanley lifted their target price on STERIS from $240.00 to $260.00 and gave the stock an "equal weight" rating in a report on Monday, May 19th. Wall Street Zen upgraded shares of STERIS from a "buy" rating to a "strong-buy" rating in a research note on Saturday. Finally, Jefferies Financial Group initiated coverage on shares of STERIS in a research note on Thursday, May 29th. They issued a "hold" rating and a $263.00 price objective for the company. Three investment analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $263.83.
Read Our Latest Analysis on STE
About STERIS
(
Free Report)
STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.
Recommended Stories

Before you consider STERIS, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and STERIS wasn't on the list.
While STERIS currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.